Emotions consist of bodily sensations and emotional concepts. This study examined how sensitivity to bodily sensations and emotional vocabulary size, which encompasses knowledge of emotional concepts, independently impact depression, and whether mindfulness can modulate these effects. A cross-sectional online survey involving 470 participants assessed the influence of somatosensory sensitivity...
This study aims to investigate the acute and sustained antidepressant effects of repeated ketamine infusions in patients with treatment-resistant depression (TRD), and to identify early metabolomic changes predictive of treatment outcomes using metabolome analyses. This open-label study investigated the effects of four intravenous ketamine infusions (0.5 mg/kg) administered over 2 weeks in 30...
NeuropsychopharmacologyJuly 15, 2025Maria Beatriz Bistue Millón, Laura Noguera, Diana Bruno et al.4 citations
This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of 5-MeO-DMT, administered at sub-psychedelic doses to adults with moderate to high levels of anxiety and/or depression, without formal psychiatric diagnosis or ongoing treatment. Using a double-blind, placebo-controlled design, participants received a...
Intranasal (IN) esketamine was approved as a therapy for treatment-resistant depression in March 2019. There continues to be interest in the field to better understand factors associated with response to treatment. The aim of the current study is to assess the association between BMI and response to esketamine. A retrospective analysis was conducted on all patients treated with intranasal...
Ketamine and electroconvulsive therapy (ECT) are among the recommended treatments for treatment resistant depression (TRD). However, there is a subset of patients who do not respond to either treatment, making it insufficient to address their condition. To determine the efficacy of concurrent therapy with ECT and intravenous racemic ketamine in TRD. This retrospective study included a total of...
Depression and PTSD are prevalent psychiatric conditions that often co-occur and significantly impact quality of life. Ketamine has emerged as a promising rapid-acting treatment for both conditions, while traditional treatments like psychotherapy typically require weeks to show effects. This study investigated whether combining ketamine with psychotherapy produces greater symptom improvement...
Previous studies have found that self-compassion and mindfulness are negatively related to depressive and anxiety symptoms. Still, the mechanisms underlying these relationships in major depression and whether such mechanisms differ in healthy people are poorly understood. In the present study, it was examined whether mindfulness and worrying mediated relationships between self-compassion,...
Ketamine infusion therapy has gained recognition as an innovative treatment for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects. Its therapeutic promise is increasingly understood to involve molecular and neurobiological processes that promote neural plasticity and cognitive flexibility. These changes may create a unique window for psychotherapeutic...
3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has shown promising safety and efficacy in phase 3 studies of post-traumatic stress disorder, but has not been investigated for a primary diagnosis of major depressive disorder (MDD). We aimed to explore the proof of principle and safety as a first study with MDMA-AT for MDD, and to provide preliminary efficacy data. Twelve...
Treatment-resistant major depression (TRD) poses a significant challenge in psychiatry due to the limited response to conventional therapies. Subanesthetic dose intravenous (IV) ketamine has emerged as an effective therapeutic option, providing rapid effects on depressive and suicidal symptoms. This article outlines the ketamine infusion protocol implemented in a general hospital, following...